D. E. Shaw & Co., Inc. Arbutus Biopharma Corp Transaction History

D. E. Shaw & Co., Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.98 - $3.17 $39,002 - $62,442	-19,698 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$2.42 - $3.98 $7,748 - $12,743	-3,202 Reduced 13.98%	19,698 $59,000
Q4 2021 Feb 14, 2022	BUY	$3.11 - $4.61 $71,219 - $105,569	22,900 New	22,900 $89,000
Q3 2019 Nov 14, 2019	SELL	$1.34 - $2.4 $25,862 - $46,320	-19,300 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$1.46 - $4.44 $41,970 - $127,636	-28,747 Reduced 59.83%	19,300 $40,000

Q4 2018 Feb 14, 2019	SELL	$3.5 - $9.66 $43,781 - $120,836	-12,509 Reduced 20.66%	48,047 $184,000
Q3 2018 Nov 14, 2018	SELL	$7.85 - $12.35 $3.22 Million - $5.06 Million	-409,952 Reduced 87.13%	60,556 $572,000
Q2 2018 Aug 14, 2018	SELL	$5.0 - $7.35 $1.2 Million - $1.76 Million	-239,954 Reduced 33.77%	470,508 $3.44 Million
Q1 2018 May 15, 2018	SELL	$4.4 - $6.05 $2.18 Million - $3 Million	-495,663 Reduced 41.1%	710,462 $3.55 Million
Q4 2017 Feb 14, 2018	SELL	$4.45 - $7.7 $2.44 Million - $4.22 Million	-547,980 Reduced 31.24%	1,206,125 $6.09 Million
Q3 2017 Nov 14, 2017	BUY	$3.4 - $7.0 $5.96 Million - $12.3 Million	1,754,105	1,754,105 $10.9 Million

130

82.2M

4.82M

546K

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $510M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.